Sarah Boseley Health editor
Thu 23 Apr 2020 15.35 EDTLast modified on Thu 23 Apr 2020 17.11 EDT




The antiviral medication remdesivir. The WHO said a document on the drug’s efficacy in treating the novel coronavirus still awaited peer review. Photograph: Reuters
Remdesivir, a drug thought to be one of the best prospects for treating Covid-19, failed to have any effect in the first full trial, it has been revealed.

The drug is in short supply globally because of the excitement it has generated. It is one of the drugs Donald Trump claimed was “promising”.

In a “gold standard” trial of 237 patients, some of whom received remdesivir while others did not, the drug did not work. The trial was also stopped early because of side-effects.

News of the failure was posted on a World Health Organization clinical trials database, but later removed. A WHO spokesman said it had been uploaded too soon by accident.

“A draft document was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is undergoing peer review and we are waiting for a final version before WHO comments,” said Tarik Jasarevic, a WHO spokesperson.

The drug, made by the US company Gilead Sciences, is an antiviral that was trialled in Ebola, but which failed to show benefits in Africa.

In the race for drugs that might work against Covid-19, many doctors have given remdesivir to patients on “compassionate grounds” without waiting for trials. Because of the interest in it, the world’s biggest trial of possible treatments for Covid-19 at Oxford has not been able to include it, because researchers could not obtain supplies.

The trial of the drug in China, on patients with severe Covid-19 symptoms, may give some doctors pause. Gilead, however, claimed there were still signs that it could be useful, possibly in patients with milder versions of disease.

In the trial, 158 patients were randomly assigned to be given remdesivir, while 79 others had standard care with a placebo instead. There was no difference between the groups with respect to recovery time. Just under 14% of those on remdesivir died, compared with nearly 13% of those not taking the treatment.


“In this study of hospitalised adult patients with severe Covid-19, [which] was terminated prematurely, remdesivir was not associated with clinical or virological benefits,” said the report on the WHO website.

The report added: “Remdesivir was stopped early in 18 (11.6%) patients because of adverse effects, compared with 4 (5.1%) in the control group.” There were no details in the short report of the side effects that caused the trial to be halted.

Just a week ago, it emerged that researchers in Chicago were excited by the results of a Gilead-run trial of remdesivir in 125 patients. Nearly all those people were discharged within a week, according to STAT News, which follows the pharmaceutical industry. However, there was no placebo group, which meant researchers could not be sure that it was the drug that made the difference, and not something else.

Remdesivir is one of a handful of drugs that have been enthusiastically backed by doctors and politicians as potential cures for Covid-19. There has also been a rush to give patients hydroxychloroquine, a less toxic version of the antimalarial chloroquine. That has led to shortages for people who need to take it for lupus, a disease that affects the immune system.

Scientists who want to see proper trials conducted are likely to point to the remdesivir trial failure as strong evidence of the dangers of giving out even tested drugs on compassionate grounds for a disease that is so novel.

America faces an epic choice...
... in the coming year, and the results will define the country for a generation. These are perilous times. Over the last three years, much of what the Guardian holds dear has been threatened – democracy, civility, truth. This administration has cleared out science and scientists across all departments. America's reputation as a competent global leader is in peril. Truth is being chased away. But with your help we can continue to put it center stage.

Rampant disinformation, partisan news sources and social media's tsunami of fake news are no bases on which to inform the American public in 2020. We believe every one of us deserves equal access to fact-based news and analysis. So we’ve decided to keep Guardian journalism free for all readers, regardless of where they live or what they can afford to pay. This would not be possible without the generosity of readers, who now support our work from across America in all 50 states.

https://www.theguardian.com/world/2020/apr/23/high-hopes-drug-for-covid-19-treatment-failed-in-full-trial

What of that of Madagascar?

Let's continue... There is always a cash out day.. One drug will surely work

Bilabong:
What of that of Madagascar?

The Madagascar tea abi?

And some scientist were giving the general public false hope.

Buharidgeneral:


The Madagascar tea abi?

Madagascar has over centuries relied on roots and herbs to treat most ailments due to limited health centers, although I doubt the efficacy of this herb.

COVID19 SOLUTION WILL NOT COME FR SCIENTIFIC GYMNASTICS, BUT WILL COME FROM THE SPIRIT OFGOD THROUGH CHRIST JESUS
WHITEMAN NO GET THE ANSWER,ONLY DEVOTED RELIOUS AFRICANS HAS THE ANSWER.

God help us ooo

They should not be discouraged, after all, all medicines were invented/discovered through trial and error.

Bad news

Buharidgeneral:


The Madagascar tea abi?

Yes na. so u follow me see am

Chaiiiii...China don finish the world.